Brind.
  1. BrainsWay Ltd. provided a strategic investment to Neurolief, which is awaiting FDA approval for its drug Proliv™Rx.

Brainsway Ltd. secured a strategic investment that is expected to expand its market reach.

2 reports, 2 independent Updated Aug 23
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Brainsway Ltd. secured a strategic investment that is expected to expand its market reach.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Strategic investment expands BrainsWay's market reach.1 source
  2. The strategic investment between Brainsway and Neurolief is intended to expand market reach.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksBWAY Shares Rise on Strategic Investment in Neurolief's At-Home Care BrainsWay Ltd. BWAY recently took a strategic step to expand its reach in the mental health market through a $5 million investment
  • GlobeNewswireBrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd. This investment marks BrainsWay’s entrance into the mar